The OS for women’s health — taken as seriously as the rest of medicine
iksa is the harness for n‑of‑1 medicine. Her hormone therapy stays a live decision for years, with what she reports reaching her nurse and your reasoning there when a headline frightens her.
Any one of these readings can change the route, the timing, or whether she starts hormones or a nonhormone treatment instead
For years you have watched this medicine get waved off as hot flashes, and since each woman you follow is her own trial of one, the first prescription is only the first time you’ll have to decide. A nonhormone treatment means one such as a neurokinin receptor antagonist. FDA is taking the boxed warnings on cardiovascular disease, breast cancer and probable dementia off menopausal hormone therapy labels, apart from the endometrial one on systemic estrogen alone. The WHI gave oral estrogen to women mostly past 60 and supports starting before 60 for symptoms, not to prevent chronic disease. The Menopause Society’s 2022 position statement finds the balance favorable under 60 or within ten years of her last period, so you read her own risk on both sides of that line.
- Coronary calciumHer 10-year risk is what the guidance steers on, with ApoB, Lp(a), blood pressure and a pregnancy history of preeclampsia or gestational diabetes behind it. A calcium score is your addition: the menopause guidance doesn’t ask for one, and the WHI’s own substudy read calcium as an endpoint. Zero at 51 can’t show non-calcified plaque, so it informs the decision and never clears her. Once before therapy, with any repeat three to seven years out on MESA’s data, and only if the answer would change her plan.
- DEXAYou read T-scores at the spine and hip past menopause and Z-scores before it, take FRAX from the femoral neck and judge a repeat by the scanner’s least significant change. SWAN puts the fastest loss from the year before her last period to two years after, so osteopenia tells you whether therapy has a second job, holding bone. Every two years, on the same scanner.
- Mammogram, density and breast MRIDensity D masks cancer and opens the question of supplemental MRI, which the ACR recommends for women who want supplemental screening and the USPSTF finds insufficient evidence for. A pathogenic BRCA1 or BRCA2 variant settles it, with annual MRI begun at 25 to 30 beside the yearly mammogram. The MRI baseline comes before therapy, because hormones can raise density and background enhancement. Breast risk differs by whether she takes a progestogen: in the WHI’s oral arms, relative risk 1.27 with a progestin and 0.79, its interval crossing 1, on estrogen alone after hysterectomy (Cochrane). Followed past 20 years, estrogen plus a progestin still raised incidence with no significant change in breast cancer deaths, while estrogen alone lowered both, HR 0.78 and 0.60 (JAMA, 2020). Mammogram yearly. Breast MRI yearly for her, every two years in the DENSE trial.
- Symptoms, estradiol and bleedingWhat she reports about hot flashes, sleep, mood, genitourinary symptoms and bleeding sets the dose, since in perimenopause estradiol and FSH swing too widely to set it alone. A serum estradiol shows what a transdermal route is delivering when symptoms persist, and bleeding past six months on therapy gets an endometrial ultrasound. Her symptoms at baseline, three months after any change and when she says they’ve moved, and whether she still needs it periodically, as the labels say.
Her doctor treated the hot flashes by a route and on a schedule her heart, bones and breasts had already set
A calcium score of zero at 51 meant no detectable calcium and no more, and she went transdermal because oral estrogen raised clot risk where transdermal didn’t, in observational data (The BMJ).
We’d like to start where your program weighs symptoms that say treat against a density or a family history that gives you pause.
Request a walkthroughRequest a walkthrough for women’s healthThe trials this medicine argues over put a paid team around each woman, and yours know their doctor and nurse by name
A coordinator held her to her mammograms, a data manager chased the bleeding reports and a statistician worked out what happened to her. With no such payroll around one woman, those jobs land on your list.
Study visits
No two women on your list are on the same mix of yearly mammogram, MRI for density, two-year DEXA and three-month review, all of it tracked by hand.
Outside results
She arrives with years of outside labs and a careful spreadsheet of her symptoms, and a chart built for one visit at a time has nowhere to put them.
Safety reporting
Bleeding nine months into therapy needs her last ultrasound in front of whoever answers, and when her message comes in, that report is in a file nobody has open.
Biostatistics
A spine that moved a little may be bone or the scanner, and when she asks whether the dose brought her sleep back, the careful answer may be a better month.
The decision to start is made once and reopened for years, at the three-month review, at Year 1 and whenever a headline frightens her
When she reports that the bleeding has changed, the harness takes that in beside her labs and the plan her doctor set, and what it finds goes to the nurse or doctor whose call it is.
Continuing therapy at Year 1 starts with asking her record what has come in since Month 2 that bears on it
What comes back quotes the notes and reports it draws on, each cited, and tells you when the record is silent on something she told you in the room.
Clinical Intelligence: clinical AI and lab trackingHer nurse comes to the three-month review with the labs her doctor is watching, listed by marker and status
Your nurse clears her flagged cards before the review. A woman’s first note about night sweats gets an Agentic CRM draft of what your approved answers can cover, your team has the last word on it, and the medical part goes to a person.
Agentic CRM: scheduling and follow-upWhen the news says the warning came off, she can ask why she still takes a progestogen and have her doctor’s reasoning explained
Patient AI knows her protocol and history and can explain her results and therapy from them, and if she wants to stop she hears that’s her doctor’s call and, with her yes, her nurse is told.
Patient AI: the treatment companion
The field still argues over timing, route and progestogen, and your notes already say, woman by woman, which you chose and why
Past the ten-year window, whoever decides whether she continues can see why she started and on what, since each reading keeps its date and its report, and each plan item the note it came from. Across the women you follow, de‑identified and with their consent, those reasons are where a first study with a research group and an IRB would begin. What a first study from your practice would take →
The questions a menopause physician brings to us
Will it second-guess what I prescribe, to me or to her?
You decide.It won’t argue with a prescription, and your decision stays yours, in your note. What she hears from Patient AI explains what you wrote, and if she asks about stopping it tells her that’s your call and, if she wants, flags it to your nurse.
Who hears about a change in bleeding?
Your nurse or you.New or heavier bleeding gets safety questions first and, when it needs a person, reaches your nurse or you on a card that says what she’s told it, what’s still unknown and why it came to you. Her last ultrasound report stays on her record for whoever opens that card.
Her density went from C to D between two readers. Which one does iksa keep?
The one you wrote.Both reports stay on file under their dates. iksa reads what your note says about them, so the density on her record is the one you wrote down.
She brings years of labs from places I’ve never heard of. Can I trust what I’m looking at?
It’s checked first.A lab value reaches you only after it’s re‑found on the source page and passes unit, range, flag and identity checks, and a value that fails is held back with the failed check named beside it.
Her symptoms set the dose. Do they stay on the record?
In her thread and your note.What she writes to Patient AI stays in her conversation with its date, where your nurse can read it, and the most recent of it reaches Clinical Intelligence beside her labs and your notes. What you weighed at the review goes in your note.
I’ve changed EHRs more times than I want to. Is this another one?
It sits beside yours.Each visit stays in your EHR and the calendar in your booking system, while iksa reads those charts by connection or by upload and holds her plan, her reports and your decisions alongside them.
Is this one more OS for women’s health, like the women’s health clinic software in my inbox?
Not the one in your inbox.We call it the harness for n‑of‑1 medicine, because a woman’s therapy is a decision you keep remaking long after the first prescription, and it keeps those decisions in front of you with what they rested on.
What is n‑of‑1 medicine?All practicesiksa beside your EHRProtocol management softwareWhat iksa adds
Your menopause program has a decision you keep going back to, and that’s where we’d begin
Bring a protocol you run. We’ll walk one patient through it.